DE60231833D1 - Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne - Google Patents

Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne

Info

Publication number
DE60231833D1
DE60231833D1 DE60231833T DE60231833T DE60231833D1 DE 60231833 D1 DE60231833 D1 DE 60231833D1 DE 60231833 T DE60231833 T DE 60231833T DE 60231833 T DE60231833 T DE 60231833T DE 60231833 D1 DE60231833 D1 DE 60231833D1
Authority
DE
Germany
Prior art keywords
neuregulin
binding domain
heparin binding
proteoglycane
heparansulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231833T
Other languages
German (de)
English (en)
Inventor
Jeffrey A Loeb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Application granted granted Critical
Publication of DE60231833D1 publication Critical patent/DE60231833D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60231833T 2001-07-31 2002-07-31 Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne Expired - Lifetime DE60231833D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30856301P 2001-07-31 2001-07-31
PCT/US2002/024053 WO2003012045A2 (en) 2001-07-31 2002-07-31 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans

Publications (1)

Publication Number Publication Date
DE60231833D1 true DE60231833D1 (de) 2009-05-14

Family

ID=23194471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231833T Expired - Lifetime DE60231833D1 (de) 2001-07-31 2002-07-31 Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne

Country Status (8)

Country Link
US (1) US7527794B2 (enExample)
EP (1) EP1456239B1 (enExample)
JP (1) JP4314113B2 (enExample)
AT (1) ATE427317T1 (enExample)
AU (1) AU2002322762B2 (enExample)
CA (1) CA2455830C (enExample)
DE (1) DE60231833D1 (enExample)
WO (1) WO2003012045A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005271902B2 (en) * 2004-07-09 2011-12-08 Wayne State University Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US20110034383A1 (en) * 2007-10-15 2011-02-10 Institut Pasteur Cxcl12 gamma a chemokine and uses thereof
EP2346526A2 (en) * 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
US8961981B2 (en) 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2020142587A1 (en) 2019-01-03 2020-07-09 The Board Of Trustees Of The University Of Illinois Method and kit for treating a neurodegenerative disease
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
WO1994008007A1 (en) 1992-09-29 1994-04-14 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP2000510879A (ja) 1995-09-05 2000-08-22 ケンブリッジ ニューロサイエンス,インコーポレイテッド 特異的なオリゴ糖−ニューレグリン相互作用のためのアナログおよびその使用
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
WO1998043649A2 (en) 1997-03-28 1998-10-08 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
AU4469997A (en) * 1997-09-17 1999-04-05 Urs Eppenberger Heregulin-gamma
GB2363714B (en) 1998-04-23 2004-03-03 Vladimir Leko Herbal composition and medicament against diabetes mellitus type II manufactured thereof
CA2325919C (en) * 1999-01-29 2009-07-21 Kaneka Corporation Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives

Also Published As

Publication number Publication date
EP1456239A4 (en) 2005-04-27
AU2002322762B2 (en) 2008-10-16
JP4314113B2 (ja) 2009-08-12
CA2455830A1 (en) 2003-02-13
US20050107601A1 (en) 2005-05-19
WO2003012045A3 (en) 2004-07-01
ATE427317T1 (de) 2009-04-15
US7527794B2 (en) 2009-05-05
EP1456239A2 (en) 2004-09-15
EP1456239B1 (en) 2009-04-01
CA2455830C (en) 2012-10-09
JP2005500052A (ja) 2005-01-06
WO2003012045A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
ATE427317T1 (de) Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane
NO20001600L (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
ATE384798T1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
NO20001599L (no) Apolipoprotein A-1 agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
NZ595498A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
PL341524A1 (en) Novel receptor coupled wih g protein
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
BR9710357A (pt) Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
ATE484587T1 (de) Ldcam genannte moleküle
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
ATE290595T1 (de) Gamma-heregulin
Davis et al. Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin
ATE372384T1 (de) Protein-tyrosin-phosphatase ptp-s31
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
WO2006017184A3 (en) HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
TR200200253T2 (tr) Proteinlerin üretimi
DE69929183D1 (de) G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung
Klatt et al. The matrilin-3 VWA1 domain modulates interleukin-6 release from primary human chondrocytes
BR0007816A (pt) Fator de estimulação óssea
ATE260339T1 (de) Antikörper gegen menschliches restrictin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition